Company news

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) news

Oric Pharmaceuticals, Inc. news releases on 6ix. Latest, Jul 16, 2024: ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners…

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) news

Press releases — page 2

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Announces $85 Million Private Placement Financing

ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones

ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference

ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update

ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference

ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call

ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting